WaveMan
WaveMan · Company
UFPT · Ufp Technologies Inc
> Search tickers & screens ⌘K
LIVE
← All companies

UFPT UFP Technologies (UFPT) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0000914156
Quote by TradingView
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
141
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $362.5K priced

What the filings say about UFPT

Insiders, 180 days
-$13.6M net sold
6 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$13.0M
6 notices

UFP Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, UFP TECHNOLOGIES INC insiders sold a net $13.6M of stock across 187 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
KOZIN MARC D
Director
SELL
2026-08-27 SECtraded 2026-08-25
3,650
$1.1M
-1.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 14.9% of the 24,462 shares held after it.
  • 4 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KOZIN MARC D sold about $1.1M of UFPT on Aug 25, 2026; 4 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
KOZIN MARC D
Director
SELL
2026-08-27 SECtraded 2026-08-25
3,350
$1.0M
-1.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.9% of the 21,112 shares held after it.
  • 4 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KOZIN MARC D sold about $1.0M of UFPT on Aug 25, 2026; 4 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
Hudson Symeria
Director
SELL
2026-08-19 SECtraded 2026-08-18
298
$95.1K
-3.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 14, 2026.
  • The trade is 32.1% of the 927 shares held after it.
  • 4 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hudson Symeria sold about $95.1K of UFPT on Aug 18, 2026; 4 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
Hudson Symeria
Director
SELL
2026-08-17 SECtraded 2026-08-14
1,926
$625.1K
-6.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 11, 2024.
  • The trade is 157.2% of the 1,225 shares held after it.
  • 4 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hudson Symeria sold about $625.1K of UFPT on Aug 14, 2026; 4 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
FELDMANN CYNTHIA L
Director
SELL
2026-08-17 SECtraded 2026-08-13
1,000
$324.3K
-6.1%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 12, 2026.
  • The trade is 22.3% of the 4,476 shares held after it.
  • 4 other insiders sold within 30 days.
  • 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FELDMANN CYNTHIA L sold about $324.3K of UFPT on Aug 13, 2026; 4 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.
187 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 182 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$13.6M over 180 days
-$12.6M over 90 days
below 90% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
141 funds bought in last quarter
more than 72% of Medical Devices
Revenue
+19.5% year over year
more than 71% of Medical Devices
Margin
11.3% net margin
more than 83% of Medical Devices
Buybacks
no share repurchases reported
Short interest
13.9% of the float short (float per yahoo 2026-10-26) · 9.2 days to cover · settled 2026-09-30
more than 94% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch UFPT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+47.3%12M
-7%+17%+42%+67%2025-102025-122026-022026-042026-062026-082026-10 2026-08-06 · BAILLY R JEFFREY sold $2.5M2026-08-10 · BAILLY R JEFFREY sold $2.2M2026-08-10 · BAILLY R JEFFREY sold $1.8M2026-08-07 · BAILLY R JEFFREY sold $1.4M2026-08-25 · KOZIN MARC D sold $1.1M2026-08-25 · KOZIN MARC D sold $1.0M2026-08-06 · BAILLY R JEFFREY sold $897.7K2026-05-12 · CROTEAU DANIEL C sold $635.0K2026-08-14 · Hudson Symeria sold $625.1K2026-08-06 · Holt Jason sold $348.7K2026-08-13 · FELDMANN CYNTHIA L sold $324.3K2026-06-12 · FELDMANN CYNTHIA L sold $263.1K2026-08-07 · BAILLY R JEFFREY sold $170.8K2025-11-06 · Litterio Christopher P. sold $157.3K2026-08-10 · BAILLY R JEFFREY sold $118.7K2026-08-18 · Hudson Symeria sold $95.1K2025-11-06 · Litterio Christopher P. sold $86.6K2025-11-06 · Litterio Christopher P. sold $43.6K2025-11-06 · Litterio Christopher P. sold $38.7K2026-06-12 · FELDMANN CYNTHIA L sold $24.0K2025-11-06 · Litterio Christopher P. sold $23.0K2025-12-10 · Holt Jason sold $21.4K2025-11-06 · Litterio Christopher P. sold $21.2K2025-11-06 · Litterio Christopher P. sold $19.7K2025-11-06 · Litterio Christopher P. sold $12.8K2025-11-06 · Litterio Christopher P. sold $10.3K2025-11-06 · Litterio Christopher P. sold $2.3K2026-08-25 · KOZIN MARC D filed to sell $2.1M2026-08-14 · Symeria Hudson filed to sell $625.1K2026-08-13 · Cynthia Feldmann filed to sell $324.3K2026-08-06 · Jason D Holt filed to sell $348.7K2026-08-06 · John B. Bailly as Trustee of The R. Jeffrey Bailly Irrevocable Trust of 2022 filed to sell $9.2M2026-08-06 · Litterio Christopher P. filed to sell $322.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns UFPT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
1,141,410 sh
$302.6M
CONGRESS ASSET MANAGEMENT CO
687,439 sh
$182.3M
WASATCH ADVISORS LP
683,262 sh
$181.2M
NEUBERGER BERMAN GROUP LLC
537,038 sh
$142.4M
Boston Trust Walden Corp
336,278 sh
$89.2M

Congress trades in UFPT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

UFPT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
KOZIN MARC D
Filed 2026-08-25
$2.1M
Symeria Hudson
Filed 2026-08-14
$625.1K
Cynthia Feldmann
Filed 2026-08-13
$324.3K
Jason D Holt
Filed 2026-08-06
$348.7K
John B. Bailly as Trustee of The R. Jeffrey Bailly Irrevocable Trust of 2022
Filed 2026-08-06
$9.2M

UFPT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
DIAMOND HILL SMALL CAP FUND
$12.7M position · as of 2026-06-30
4.1%
Wasatch Long/Short Alpha Fund
$1.3M position · as of 2026-06-30
3.4%
Motley Fool Small-Cap Growth ETF
$1.9M position · as of 2026-05-31
3.3%
Wasatch Small Cap Growth Fund
$37.0M position · as of 2026-06-30
3.1%
Brown Capital Management Small Company Fund
$10.0M position · as of 2026-06-30
3.1%
Ranger Micro Cap Fund
$324.8K position · as of 2026-07-31
2.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · R. Jeffrey Bailly
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.6M
$8.2M
$1.8M
+376%
+13%
2024
$5.3M
$9.5M
$1.3M
+424%
+13%
2023
$4.9M
$8.4M
$1.1M
+269%
+2%
2022
$4.3M
$6.6M
$1.0M
+153%
-17%
2021
$2.6M
$4.1M
$712.2K
+51%
+4%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $13.6M sold by insiders over 180 days, 141 funds added last quarter, $13.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

UFPT financials

Revenue growth
+19.5%
XBRL, annual
Net margin
11.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$631.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+11.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$60.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.25x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.61x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+17.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+11.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+14.8%
operating income after a 18.4% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+16.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
31.77x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$2.4B
market value at close 2026-10-27 on 2026-07-27 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+2.7%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
4.22x
P/E over trailing EPS growth of 8%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$602.8M$504.4M$400.1M$353.8M
Gross profit$170.4M$146.7M$112.2M$90.3M
Operating income$92.3M$80.9M$57.7M$55.4M
Net income$68.3M$59.0M$44.9M$41.8M
EPS (diluted)8.757.585.835.45
Operating cash flow$91.9M$66.6M$41.3M$17.7M
Cash$20.3M$13.4M$5.3M$4.5M
Long-term debt$123.0M$176.9M$28.0M$51.0M
SEC XBRL, fiscal years, as known on 2026-10-28

UFPT Stock Sonar score 6/7 axes

Find similar shapesCompare

UFPT ranks highest on profitability (82nd percentile) and institutional and government (72nd), and lowest on insider conviction (4th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
82
Inputs
  • Return on equity+17.1% · 87 pct, sector of 183
  • Return on assets+11.0% · 89 pct, sector of 214
  • Return on invested capital+14.8% · 63 pct, sector of 36
  • Return on capital employed+16.5% · 91 pct, sector of 188
Financial health
71
Inputs
  • Debt to equity0.25x · 54 pct, sector of 159
  • Cash flow to debt0.61x · 87 pct, sector of 150
Growth
71
Inputs
  • Revenue growth, YoY+19.5% · 71 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
4
Inputs
  • Net Form 4 buying (codes P and S), 180d-$13.6M · 9 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
72
Inputs
  • Funds adding, latest quarter141 · 72 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
40
Inputs
  • Short interest, % of float+13.9% · 10 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+27.7% · 8 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

UFPT filings, in plain words

Are UFP Technologies insiders buying or selling UFPT?

In the 180 days to 2026-10-28, UFP Technologies insiders were net sellers, a net $13.6M across purchases and sales reported on Form 4, by 6 sellers.

Are there planned insider sales of UFPT?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $13.0M of stock; the latest, by KOZIN MARC D, was filed 2026-08-25.

Read the full summary

In the 180 days to 2026-10-28, UFP Technologies insiders were net sellers of UFPT, a net $13.6M across purchases and sales reported on Form 4 by 6 sellers. None of the 16 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $13.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies